Current approach to androgen deprivation therapy in patients with advanced prostate cancer

European Urology, Supplements

Volumn 9, Issue 11, 2010, Pages 776-781

  Heidenreich, Axel ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Androgen deprivation therapy; EAU; Guidelines; Intermittent; Prostate cancer; PSA

Indexed keywords

GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER RELAPSE; CLINICAL TRIAL; HUMAN; MEDICAL DECISION MAKING; METASTASIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW;

EID: 78649861194     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2010.11.001     Document Type: Review

References (22)

1. Heidenreich A, Bolla M, Joniau S, et al. Guidelines on prostate cancer. European Association of Urology Web site. Updated 2010. http://www.uroweb.org/gls/pdf/Prostate%20Cancer%202010.pdf.
2. Ferlay J., Parkin D.M., Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe 2008. Eur J Cancer 2010, 46:765-781.
3. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
4. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998, 280:969-974.
5. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 2003, 170:S21-S27.
6. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999, 341:1781-1788.
7. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 2006, 7:472-479.
8. Heidenreich A., Ohlmann C.H., Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 2007, 52:29-37.
9. Heidenreich A., Varga Z., Von Knobloch R. Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: high incidence of lymph node metastasis. J Urol 2002, 167:1681-1686.
10. Briganti A., Karnes J.R., Da Pozzo L.F., et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N+ patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009, 55:261-270.
11. Moul J.W., Wu H., Sun L., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004, 171:1141-1147.
12. Schröder F.H., Kurth K.H., Fosså S.D., et al. Early versus delayed endocrine treatment of pN1-3 M0 prostate cancer without local treatment of the primary tumor: results of European Organisation for the Research and Treatment of Cancer 30846-a phase III study. J Urol 2004, 172:923-927.
13. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. Clin Oncol 2006, 24:1868-1876.
14. Schröder F.H., Kurth K.-H., Fosså S.D., et al. Early versus delayed endocrine treatment of T2-T3 pN1-3 M0 prostate cancer without local treatment of the primary tumour: final results of European Organisation for the Research and Treatment of Cancer protocol 30846 after 13 years of follow-up (a randomised controlled trial). Eur Urol 2009, 55:14-22.
15. Studer U.E., Collette L., Whelan P., et al. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891). Eur Urol 2008, 53:941-949.
16. Mottet N., Lucas C., Sene E., Avances C., Maubach L., Wolff J.M. Intermittent androgen castration: a biological reality during intermittent treatment in metastatic prostate cancer?. Urol Int 2005, 75:204-208.
17. Albrecht W., Collette L., Fava C., et al. Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study. Eur Urol 2003, 44:505-511.
18. Gleave M.E., Hsieh J.T., Wu H.C., von Eschenbach A.C., Chung L.W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res 1992, 52:1598-1605.
19. Akakura K., Bruchovsky N., Goldenberg S.L., Rennie P.S., Buckley A.R., Sullivan L.D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer 1993, 71:2782-2790.
20. Calais Da Silva F., Bono A., Whelan P., et al. Phase III study of intermittent MAB versus continuous MAB - an international cooperative study - quality of life. Eur Urol Suppl 2006, 5:289. Abstract 1066.
21. Hussain M., Tangen C.M., Higano C., et al. Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006, 24:3984-3990.
22. Boccon-Gibod L., Hammerer P., Madersbacher S., Mottet N., Prayer-Galetti T., Tunn U. The role of intermittent androgen deprivation in prostate cancer. BJU Int 2007, 100:738-743.